During the quarter, the health care sector was the biggest contributor to Fund performance. Health care companies overall reported strong earnings in the first half, showing continued growth momentum. Among our health care holdings, Sinopharm Group (HKSE:01099), one of China’s largest pharmaceutical products distributors, and Sino Biopharmaceutical (HKSE:01177) were top contributors. Sino Biopharmaceutical has been focusing on new drug R&D, and its efforts are paying off as the company has found solid contribution from new products.
From Matthews China Fund (Trades, Portfolio)’s Q3 2014 Commentary.
